Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
First-in-class blood test for lung cancer: Advancing early detection with proteomics and explainable AI (Oxcan)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: United Kingdom
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Lung cancer is the leading cause of cancer-related deaths globally, with over 250,000 annual deaths in Europe. Early detection drastically improves survival rates, but existing screening methods, like low-dose computed tomography (LDCT), can be costly with lower throughput and under-utilized. Oxford Cancer Analytics (OXcan) addresses this gap by developing a simple, cost-effective, and minimally invasive blood test using advanced proteomics and explainable machine learning (ML). Our patent filed ML pipeline identifies focused protein biomarker panels with exceptional sensitivity and specificity, outperforming traditional genomic-based competitors. The innovation integrates a cutting-edge, four-step process using proteomics and tailored ML algorithms to distill a focused molecular signature that detects early-stage lung cancer with unprecedented accuracy. Designed for global scalability, the immunoassay-based test seamlessly integrates into existing healthcare systems without specialized infrastructure. By offering a cost-effective blood molecular signature, our technology democratises access to early cancer detection, particularly in underserved and disadvantaged population groups, potentially saving millions of lives and reducing healthcare costs. OXcan's mission is to revolutionise cancer detection through proactive, accessible, and highly accurate solutions, achieving UN SDG 3 targets of reducing cancer mortality and promoting healthcare equity worldwide.

Keywords: lung cancer screening,cancer detection,protein immunoassay,explainable machine learning for cancer detection,cancer biomarkers,liquid biopsy
Development and Commercialization of ShelfSight, an AI-Powered Visually Intelligent Retail Solution for Operational Excellence and Sales Optimization. (ShelfSight)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Türkiye
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 3600000.0
EU funding (EUR): 3600000.0
Participants: 1
Project status: SIGNED

Vispera is a pioneering retail image recognition and analytics company, specializing in providing Software-as-a-Service (SaaS) solutions to Retailers. Our cutting-edge technology empowers clients with real-time retail execution tracking, auditing, and productivity enhancement tools, ultimately enabling perfect store enablement. Through our comprehensive suite of services, we deliver crucial retail execution data including on-shelf availability (OSA), planogram compliance, shelf share, price tag readings, point-of-sale branding visibility, competitive intelligence, and more. Utilizing image recognition-based automation, we offer clients objective insights into their in-store performance, enabling them to take immediate corrective actions to enhance the shopping experience and prevent lost sales opportunities. Traditional retail operations suffer from manual, error-prone procedures and a lack of real-time monitoring and control mechanisms. This outdated approach leads to inefficiencies such as stockouts, planogram non-compliance, pricing errors, and delayed reporting, negatively impacting customer satisfaction and overall profitability. Vispera's ShelfSight disrupts the retail landscape by automating monitoring and control processes, reducing human error, cutting costs, and accelerating reporting times. By leveraging AI, machine learning, and deep learning technologies, our image recognition system provides super accurate, timely, and granular data that can be seamlessly integrated into enterprise systems. The urgency for such a solution is underscored by industry statistics, with global retailers missing out on approximately $1.2 trillion in sales annually due to out-of-stock situations, and inefficient shelf replenishment strategies contributing to 28% of stockouts. In the EIC project, the company aims to optimize the solution and validate it with pilot partners followed by market entry in Europe.

Keywords: image recognition perfect stores planogram compliance
The first food-based negative filling agent to reshape the landscape of small bowel image-based diagnostics (Lumentin)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Misdiagnosis or delayed diagnosis of gastrointestinal conditions can lead to unnecessary surgeries, extended hospital stays, increased healthcare expenses, disease progression, poorer health outcomes, and decreased quality of life. Current oral contrast agents used in CT do not offer adequate imaging quality, and the need for a negative contrast agent has been recognized since the 1980s. Lumentin is a groundbreaking food-based and HU-negative (black on CT) oral contrast agent for abdominal CT imaging. Composed of three main components, air bubbles, water and egg white protein, Lumentin provides stark black contrast on CT images. This innovation enhances the visualization of bowel loops and mucosal surfaces, improving diagnostic accuracy for conditions like Crohn's disease and tumors in proximity to or within the small bowel (which occupies 65% of the abdominal cavity). Phase I, IIa, and IIb clinical trials validated Lumentin's safety and efficacy, showing it significantly improves contrast quality with a favourable safety profile. The project's aim is to complete Phase III clinical trials to confirm Lumentin's safety and efficacy. Lumentin's commercialization potential is strong, with competitive pricing, proven efficacy, and high market interest from KOLs in the field of radiology. It provides MRI-quality imaging while maintaining the cost and speed of CT scans and a patient-friendly procedure. By offering these advantages, Lumentin extends market boundaries, enabling rapid and accessible imaging for patients who might otherwise face long waiting times, thus addressing the issue of under-diagnosis. Our project aligns with EU health policies by improving imaging of pathologies in the abdomen and pelvic region, enhancing patient care across Europe and the US. The EIC Accelerator funding will be crucial to conducting Phase III trials, achieving market approval, driving growth, and creating job opportunities within the company and its partners.

Keywords: negative contrast agent food based contrast agent computed tomography diagnostic imaging demarcation gastrointestinal disorders small bowel diseases crohn s disease abdominal and pelvic tumors
INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENT (LUMEN)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-11-01
End date: 2026-10-31
Duration (months): 24.0
Total project cost (EUR): 3561428.57
EU funding (EUR): 2493000.0
Participants: 1
Project status: SIGNED

JaxBio is a pioneering biotech startup company dedicated to transforming lung cancer diagnostics and treatment through innovative liquid biopsy and DNA-chip technology. Our team, comprised mainly of Ph.D. experts in cancer biology, data science, and technology development, is committed to addressing the critical challenge of early lung cancer detection and management. The global impact of lung cancer, claiming nearly 1.8 million lives annually, highlights the urgent need for advanced diagnostic solutions. Over 70% of lung cancer patients are diagnosed at advanced stages, resulting in poor prognosis and high mortality rates. Furthermore, approximately 50% of patients receive suboptimal treatment due to a lack of methods to predict treatment response rapidly. JaxBio addresses these challenges with LUMEN, an innovative non-invasive liquid biopsy assay. This method employs a custom chip designed for ultra-sensitive detection of epigenetic signatures in cell-free DNA, complemented by an AI algorithm for identifying disease-specific biomarkers. Our findings demonstrate LUMEN's ability to detect cancer early, even with extremely low tumor-derived DNA concentrations in the blood. Eliminating the need for DNA sequencing, LUMEN offers unparalleled accuracy in cancer detection as well as affordability. It also provides valuable insights for personalized treatment approaches and early tumor recurrence detection. With EIC support, our objective is to conduct clinical trials and complete the development of the lung cancer chip. This chip will serve as a companion diagnostic tool, predicting therapy response, and assessing treatment effectiveness. Our goal is to bring a clinically validated product to market, comprising reagents, chips, and analysis software, ultimately enhancing cancer care and patient outcomes.

Keywords: cancer diagnosis,cell free dna,liquid biopsy,lung cancer
Global decontamination: enhancing firefighter safety and working conditions (DECON GLO)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Belgium
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Decontex is a young and dynamic company founded in 2016 by engineer Thomas Verminck. Its core task is the decontamination and cleaning of personal protective equipment (PPE), in particular firefighter suits, high- visibility clothing and attributes, where regulations and professional use guarantee a critical mass. A resolute choice was made for liquid CO2 technology (LCO2) as a sustainable alternative to conventional treatments like dry cleaning with perchloroethylene (PERC) and wet cleaning with water and detergent. The LCO2 technology is based on pressurized liquid CO2 (P: 48 – 82 bar), which has physical properties that enable the medium to penetrate through and remove toxins from all textile layers that the PPE is built up of. The technology was originally developed in the early eighties by NASA with the aim of decontaminating astronaut gear. It was later licensed to Electrolux Group, which did not manage to develop a commercially viable activity with it and abandoned this technology trail. Consequently, in 2018 NASA granted a license to Decontex for the application of decontamination and cleaning of PPE. Decontex is conducting its own developments within the concept: • Between 2016 and 2020, Decontex developed and patented its own LCO2 machine; which forms the foundation of Decontex’ service offering. • In the period from 2020 to 2022, Decontex developed innovative detergents for use in conjunction with LCO2, during a collaboration with Christeyns , a major Belgian producer of hygiene solutions (chemicals) for professional textile care, food processing and retail, the professional cleaning industry, and the medical and life sciences sectors. Detergents for use in LCO2 are very different from those used in water, as CO2 is an apolar solvent. • Starting in 2022, Decontex is in the process of developing a scCO2 machine – the acronym referring to supercritical CO2 – to realize cleaning and decontamination capabilities superior to those of LCO2. Decontex sta

Keywords: decontamination,safety,health,firefighters
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor (CardioCap)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

CardioCap is the first ever multiplex and multimodal point-of-care (POC) device used for heart failure (HF) therapy management. With just a prick on the patient’s finger, and a drop of blood, healthcare professionals can deduce the severity of the HF patients’ conditions through simultaneous detection of 4 blood biomarkers, namely potassium, sodium, creatinine and NT-proBNP. With the comprehensive data generated by the 4 biomarkers, they can make prompt and informed decisions on the appropriate treatment. By optimising the drug dosage or exploring other treatment options, they can prevent patients entering acute decompensation events or adverse side effects, such as kidney failure. CardioCap is a handheld POC device that works with a drop of blood from the prick of a finger, and is as user-friendly as a glucometer. It performs at the same standard as the gold benchmarks (i.e. The Stratus CS by Siemens, COBAS CARDIAC NTproBNP+ by Roche and standard laboratory testing), but is used after patients are discharged from hospitals. With CardioCap, continuum care for HF patients is made available after hospital discharge, at the patient's home, community care centres, neighbourhood clinics and pharmacies. Re-hospitalisation rate and mortality rate is expected to be reduced by at least 30%. Furthermore, it helps to free up the hospital capacity for other emergency cases that could not be prevented. This mission is aligned with the health inequality gap in the EU, with the World Economic Forum (WEF) stating that ill health accounts for 20% of total healthcare cost. In closing the health inequality gap, the WEF urged for health initiatives such as POC that enable people to receive the health services they need.

Keywords: heart failure,medical device
The evolutionary origin of β-catenin-dependent germ layer specification (CtenoGerm)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-09-01
End date: 2028-08-31
Duration (months): 24.0
Total project cost (EUR): 202125.12
EU funding (EUR): 202125.12
Participants: 1
Project status: SIGNED

In the embryonic development of most animals, cell differentiation begins with the formation of three primary germ layers - ectoderm, endoderm, and mesoderm. A key regulator of this process is β-catenin, which activates the specification of the endoderm and mesoderm. Although β-catenin plays a central role in germ layer specification in a wide range of animals, we lack a detailed understanding of when this regulation emerged in animal evolution. By studying the embryonic development of the comb jelly Mnemiopsis leidyi, a member of the earliest branching animal lineage - Ctenophora, this project aims to determine whether β-catenin regulated endomesoderm specification in the last common ancestor of all animals. To understand the role of β-catenin in ctenophore germ layer specification, I will first characterize Mnemiopsis germ layers at the gene expression level using a single-cell sequencing approach. By comparing the results with data from other model organisms, I will determine whether Mnemiopsis germ layers are homologous to the ectoderm, endoderm, and mesoderm of other animals. Next, I will elucidate the spatial dynamics of β-catenin during germ layer specification by performing detailed immunofluorescence analysis using Mnemiopsis-specific anti-β-catenin antibodies. Finally, to assess the function of β-catenin signaling in ctenophore germ layer specification, I will analyze embryos with experimentally up- and downregulated β-catenin activity using morphological methods, gene expression analysis, and innovative 4D (3D time-lapse) microscopy. Through this research, CtenoGerm will deepen our understanding of how evolutionary changes in developmental programs have shaped the remarkable diversity of body forms across living species. By applying cutting-edge techniques in bioinformatics, molecular and developmental biology, and advancing leadership and management skills, the MSCA will be a transformative experience that will enhance my career and scientific growth.

Keywords: evolution of germ layer specification,evolution of endomesoderm,ctenophora,mnemiopsis leidyi,catenin
Systematic mapping of the chloroplast protein import system (Chloro-Import)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Cell Biology, Development, Stem Cells and R egeneration
Panel description: For all organisms : Structure and function of the cell, cell -cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: Israel
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2023-09-01
End date: 2028-08-31
Duration (months): 60.0
Total project cost (EUR): 1700000.0
EU funding (EUR): 1700000.0
Participants: 1
Project status: SIGNED

Protein import into a membrane-bound organelle in eukaryotes has been intensively studied, leading to the discovery of the central intracellular import machineries. Yet, this field has undergone a fundamental paradigm shift following recent discoveries of non-canonical import pathways in the mitochondria and ER. While the chloroplast is still thought to have but one import machinery (TIC/TOC), accumulating evidence indicate it, too, has non-canonical pathways. Technological constraints have so far barred the systematic search for alternative import pathways, as well as the exploration of central aspects relating to this import system: Are there additional import pathways other than the canonical chloroplast translocon apparatus? What ensures correct targeting of proteins in the highly crowded cytosol to the chloroplast? What mediates between quality control processes and protein import? In Chloro-Import, we will go beyond the state-of-the-art by implementing multipronged, genome-wide, unbiased approaches we developed or adopted to elucidate all the targeting pathways en route to the chloroplast in Chlamydomonas. Specifically, we will use advanced genome-wide screening to comprehensively elucidate chloroplast import pathways (Aim1); uncover the functional organization of import pathways using genetic-interaction profiling and protein-protein-interaction mapping (Aim2); and conduct an in-depth biochemical investigation of the function of unstudied/novel import factors (Aim3). To the best of our knowledge, this is the first-ever study of this scale in a photosynthetic eukaryote cell. The outcome will be a complete map of the chloroplast protein-import system (pathways, components, regulators) and a genetic platform for this system’s in-depth characterization. It will further offer insight into basic questions in chloroplast functioning, and may also pave the way to the synthetic engineering of crops that are more efficient for projected climate changes.

Keywords: high content microscopy,next generation sequencing,genetic interactions,chloroplast
Strategies and Services for Enhanced Disruption Resilience and Cooperation in Europe (ENDURANCE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Resilient Infrastructure
Action type: Innovation actions
Countries involved: Romania,Germany,Slovenia,Italy,Greece,Belgium,Ireland
Call: Facilitating strategic cooperation to ensure the provision of essential services (HORIZON-CL3-2023-INFRA-01, 2023)
Start date: 2024-10-01
End date: 2027-09-30
Duration (months): 36.0
Total project cost (EUR): 6480662.5
EU funding (EUR): 4999776.25
Participants: 23
Project status: SIGNED

Amidst an increasingly interconnected and complex world, the provision of essential services remains crucial for the well-being of European citizens and the smooth functioning of the internal market. Yet, the ever-evolving landscape of risks, ranging from cyber threats, physical attacks, and human errors to natural disasters, demands a proactive and collaborative, pan-European approach to ensuring disruption resilience. Therefore, ENDURANCE is driven by the critical need to fortify Europe’s essential services against potential disruptions, transcending the sole focus on the underlaying critical assets. Recognizing the significance of the CER and NIS2 Directives in setting the groundwork for resilience and, in parallel, the current silo approach to the Critical Infrastructure (CI) resilience and the business continuity of essential services they provide, we will assist the CI authorities across the EU in fully grasping and harmoniously implementing both directives. By comprehensively understanding and preparing for the demands of these legislative measures (and their national implementations), we aim to empower the EU MS authorities and CI operators with the know-how, methodologies, services, and strategies needed to navigate the complexities of disruption resilience effectively. With a team of 9 excellent research, technology, and business developing organisations (all with vast experience in INFRA projects), and with 7 EU MS authorities and 6 CI operators representing 6 critical sectors and 4 EU MS, ENDURANCE will: (i) Enhance strategic cooperation and collaboration among the CI stakeholders at all levels. (ii) Develop datasets, registries, methodologies, technologies, and services (at TRL6-7) for secure sharing and federated processing of CER-relevant data, joint assessment of relevant risks and resilience, and large-scale stress-testing of preparedness. (iii) Provide harmonised and pragmatic strategy for the continuity of the interconnected essential services.

Keywords: ci resilience,cer directive,nis2 directive,strategic cooperation